Seelos Therapeutics: Rises on European orphan drug tag for ALS treatment

Seelos Therapeutics

27/05/2021 18:09

** Drug developer's shares  SEEL.O  rise 3.8% to $3.2, on
course to snap four sessions of losses 
    ** SEEL receives European orphan drug designation for its
experimental treatment SLS-005, for amyotrophic lateral
sclerosis (ALS), a rare neurological disease  urn:newsml:reuters.com:*:nPn2L6kGga
    ** The tag is meant for diseases affecting not more than
five in 10,000 people in the EU
    ** Co says under designation, it stands to benefit from
several incentives such as protocol assistance, reduced
regulatory fees and market exclusivity
    ** In November, SLS-005 was granted orphan drug designation
by the U.S. FDA for ALS  urn:newsml:reuters.com:*:nL4N2I53DD
    ** Stock has more than doubled in value YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))